View Future GrowthPell Bio-Med Technology 과거 순이익 실적과거 기준 점검 0/6Pell Bio-Med Technology 의 수입은 연평균 -13.7%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 22.5%의 비율로 증가했습니다. 매출은 연평균 18.7%의 비율로 증가해 왔습니다.핵심 정보-13.66%순이익 성장률-1.73%주당순이익(EPS) 성장률Biotechs 산업 성장률12.22%매출 성장률18.71%자기자본이익률-17.00%순이익률-1,506.68%최근 순이익 업데이트30 Jun 2026최근 과거 실적 업데이트Reported Earnings • Aug 17Second quarter 2026 earnings released: NT$1.36 loss per share (vs NT$1.33 loss in 2Q 2025)Second quarter 2026 results: NT$1.36 loss per share (further deteriorated from NT$1.33 loss in 2Q 2025). Net loss: NT$88.9m (loss widened 14% from 2Q 2025).Reported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).Reported Earnings • May 14First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024)First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024).모든 업데이트 보기Recent updatesReported Earnings • Aug 17Second quarter 2026 earnings released: NT$1.36 loss per share (vs NT$1.33 loss in 2Q 2025)Second quarter 2026 results: NT$1.36 loss per share (further deteriorated from NT$1.33 loss in 2Q 2025). Net loss: NT$88.9m (loss widened 14% from 2Q 2025).New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (NT$26m revenue, or US$818k). Minor Risk Share price has been volatile over the past 3 months (9.5% average weekly change).Reported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).공고 • Mar 05Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city TaiwanNew Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).Reported Earnings • May 14First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024)First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024).공고 • May 06Pell Bio-Med Technology Co., Ltd. to Report Q1, 2025 Results on May 13, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025Reported Earnings • Mar 18Full year 2024 earnings released: NT$6.83 loss per share (vs NT$8.62 loss in FY 2023)Full year 2024 results: NT$6.83 loss per share (improved from NT$8.62 loss in FY 2023). Net loss: NT$389.4m (loss narrowed 2.3% from FY 2023).공고 • Mar 12Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,327, t`i ting ta tao, neihu district, taipei city Taiwan공고 • Mar 04Pell Bio-Med Technology Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.7% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$561k). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).분석 기사 • Feb 05Pell Bio-Med Technology (TWSE:6949) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$1.76 loss per share (vs NT$2.64 loss in 3Q 2023)Third quarter 2024 results: NT$1.76 loss per share (improved from NT$2.64 loss in 3Q 2023). Net loss: NT$100.8m (loss narrowed 15% from 3Q 2023).공고 • Nov 01Pell Bio-Med Technology Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024Reported Earnings • Aug 17Second quarter 2024 earnings released: NT$1.78 loss per share (vs NT$2.75 loss in 2Q 2023)Second quarter 2024 results: NT$1.78 loss per share (improved from NT$2.75 loss in 2Q 2023). Net loss: NT$101.5m (loss narrowed 17% from 2Q 2023).공고 • Aug 06Pell Bio-Med Technology Co., Ltd. to Report Q2, 2024 Results on Aug 13, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q2, 2024 results on Aug 13, 2024분석 기사 • Jul 22Pell Bio-Med Technology (TWSE:6949) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...New Risk • May 29New major risk - Revenue and earnings growthRevenue has declined by 3.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 3.2% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$556k).공고 • Mar 27PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024.매출 및 비용 세부 내역Pell Bio-Med Technology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TWSE:6949 매출, 비용 및 순이익 (TWD Millions)날짜매출순이익일반관리비연구개발비30 Jun 2629-43623525331 Mar 2626-42521924331 Dec 2531-42421025330 Sep 2530-37414324830 Jun 2527-35613723831 Mar 2527-38013726831 Dec 2420-38913526630 Sep 2418-38613726130 Jun 2418-40414825631 Mar 2418-42515825431 Dec 2318-39914524030 Sep 2320-36113421230 Jun 2320-31011518731 Mar 2319-2388814631 Dec 2217-2308214331 Dec 2114-18955137양질의 수익: 6949 은(는) 현재 수익성이 없습니다.이익 마진 증가: 6949는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 6949은 수익성이 없으며 지난 5년 동안 손실이 연평균 13.7% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 6949의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 6949은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(21.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 6949는 현재 수익성이 없으므로 자본 수익률이 음수(-17%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/20 19:15종가2026/08/20 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pell Bio-Med Technology Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Aug 17Second quarter 2026 earnings released: NT$1.36 loss per share (vs NT$1.33 loss in 2Q 2025)Second quarter 2026 results: NT$1.36 loss per share (further deteriorated from NT$1.33 loss in 2Q 2025). Net loss: NT$88.9m (loss widened 14% from 2Q 2025).
Reported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).
Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).
Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).
Reported Earnings • May 14First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024)First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024).
Reported Earnings • Aug 17Second quarter 2026 earnings released: NT$1.36 loss per share (vs NT$1.33 loss in 2Q 2025)Second quarter 2026 results: NT$1.36 loss per share (further deteriorated from NT$1.33 loss in 2Q 2025). Net loss: NT$88.9m (loss widened 14% from 2Q 2025).
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 9.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (NT$26m revenue, or US$818k). Minor Risk Share price has been volatile over the past 3 months (9.5% average weekly change).
Reported Earnings • May 09First quarter 2026 earnings released: NT$1.00 loss per share (vs NT$1.30 loss in 1Q 2025)First quarter 2026 results: NT$1.00 loss per share. Net loss: NT$76.6m (loss widened 1.1% from 1Q 2025).
Reported Earnings • Mar 11Full year 2025 earnings released: NT$7.23 loss per share (vs NT$6.83 loss in FY 2024)Full year 2025 results: NT$7.23 loss per share (further deteriorated from NT$6.83 loss in FY 2024). Net loss: NT$423.9m (loss widened 8.9% from FY 2024).
공고 • Mar 05Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 18, 2026. Location: no,158, hsing shan rd., neihu district, taipei city Taiwan
New Risk • Jan 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (NT$30m revenue, or US$947k). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change).
Reported Earnings • Nov 06Third quarter 2025 earnings released: NT$2.02 loss per share (vs NT$1.76 loss in 3Q 2024)Third quarter 2025 results: NT$2.02 loss per share (further deteriorated from NT$1.76 loss in 3Q 2024). Net loss: NT$118.4m (loss widened 17% from 3Q 2024).
Reported Earnings • Aug 17Second quarter 2025 earnings released: NT$1.33 loss per share (vs NT$1.78 loss in 2Q 2024)Second quarter 2025 results: NT$1.33 loss per share (improved from NT$1.78 loss in 2Q 2024). Net loss: NT$77.8m (loss narrowed 23% from 2Q 2024).
Reported Earnings • May 14First quarter 2025 earnings released: NT$1.30 loss per share (vs NT$1.56 loss in 1Q 2024)First quarter 2025 results: NT$1.30 loss per share (improved from NT$1.56 loss in 1Q 2024). Net loss: NT$75.8m (loss narrowed 11% from 1Q 2024).
공고 • May 06Pell Bio-Med Technology Co., Ltd. to Report Q1, 2025 Results on May 13, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q1, 2025 results on May 13, 2025
Reported Earnings • Mar 18Full year 2024 earnings released: NT$6.83 loss per share (vs NT$8.62 loss in FY 2023)Full year 2024 results: NT$6.83 loss per share (improved from NT$8.62 loss in FY 2023). Net loss: NT$389.4m (loss narrowed 2.3% from FY 2023).
공고 • Mar 12Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025Pell Bio-Med Technology Co., Ltd., Annual General Meeting, Jun 11, 2025. Location: 2 floor no,327, t`i ting ta tao, neihu district, taipei city Taiwan
공고 • Mar 04Pell Bio-Med Technology Co., Ltd. to Report Q4, 2024 Results on Mar 11, 2025Pell Bio-Med Technology Co., Ltd. announced that they will report Q4, 2024 results on Mar 11, 2025
New Risk • Feb 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 9.7% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$561k). Minor Risk Share price has been volatile over the past 3 months (6.5% average weekly change).
분석 기사 • Feb 05Pell Bio-Med Technology (TWSE:6949) Is In A Good Position To Deliver On Growth PlansWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • Nov 18Third quarter 2024 earnings released: NT$1.76 loss per share (vs NT$2.64 loss in 3Q 2023)Third quarter 2024 results: NT$1.76 loss per share (improved from NT$2.64 loss in 3Q 2023). Net loss: NT$100.8m (loss narrowed 15% from 3Q 2023).
공고 • Nov 01Pell Bio-Med Technology Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q3, 2024 results on Nov 08, 2024
Reported Earnings • Aug 17Second quarter 2024 earnings released: NT$1.78 loss per share (vs NT$2.75 loss in 2Q 2023)Second quarter 2024 results: NT$1.78 loss per share (improved from NT$2.75 loss in 2Q 2023). Net loss: NT$101.5m (loss narrowed 17% from 2Q 2023).
공고 • Aug 06Pell Bio-Med Technology Co., Ltd. to Report Q2, 2024 Results on Aug 13, 2024Pell Bio-Med Technology Co., Ltd. announced that they will report Q2, 2024 results on Aug 13, 2024
분석 기사 • Jul 22Pell Bio-Med Technology (TWSE:6949) Is In A Strong Position To Grow Its BusinessThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
New Risk • May 29New major risk - Revenue and earnings growthRevenue has declined by 3.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 3.2% over the past year. Revenue is less than US$1m (NT$18m revenue, or US$556k).
공고 • Mar 27PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024PELL Bio-Med Technology Co. Ltd., Annual General Meeting, Jun 12, 2024.